Review anchor
Cell membrane
SUBCELLULAR · Bacteria
As of 2026-09-13
Evidence Snapshot
Cell membrane
CHEMBL2364031
SUBCELLULAR
Bacteria
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Cell membrane as ChEMBL target CHEMBL2364031. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2364031
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Cell membrane matters
Cell membrane is reviewed as Cell membrane; Cell membrane shows approved-linked disease relevance led by infection. 5 more disease programs remain visible in the same review block.; 5 linked drugs keep this evidence frame grounded.; the current evidence base includes 0 approved drugs, 537 compounds, and 1237 assays, with lead potency reaching pChEMBL 7.2.
Protein context
Cell membrane
Cell membrane
Review this target as Cell membrane.
Protein source · UniProt accession via ChEMBL component mappingDisease context
infection
Cell membrane shows approved-linked disease relevance led by infection. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include CHLORHEXIDINE GLUCONATE, COLISTIMETHATE SODIUM, DAPTOMYCIN.
Start review with infection because it currently carries approved-linked support. Linked drugs include CHLORHEXIDINE GLUCONATE, COLISTIMETHATE SODIUM, DAPTOMYCIN, OMIGANAN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
5 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 0 approved drugs, 537 compounds, and 1237 assays for this target. The dominant activity type is IC50. CHEMBL5271959 is the current potency anchor at pChEMBL 7.2.
Use CHEMBL5271959 as the tractability anchor when discussing potency (pChEMBL 7.2).
Activity source · ChEMBL 36 via Core Engine
pChEMBL 7.2
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Cell membrane matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why infection is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
537
Total Compounds
1237
Total Assays
0
Approved Drugs
IC50: 25.0, EC50: 21.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL5271959
|
7.2 | EC50 | — |
|
|
No preferred name
CHEMBL4211294
|
7.0 | EC50 | — |
|
|
No preferred name
CHEMBL5290770
|
6.8 | EC50 | — |
|
|
No preferred name
CHEMBL5283188
|
6.8 | EC50 | — |
|
|
No preferred name
CHEMBL5291484
|
6.8 | EC50 | — |
Source Header